South Texas Clinical Research

Menu
Facebook-f Instagram Linkedin-in

CLINICAL RESEARCH STUDY

ROCHE Weight Loss Study

A Clinical Trial for Individuals with Obesity or Overweight Without Type 2 Diabetes

We are conducting a Phase 3 clinical research study evaluating the efficacy and safety of RO7795068, a dual GLP-1/GIP receptor agonist, for chronic weight management.

This study compares RO7795068 at different doses to a placebo, in conjunction with a reduced-calorie diet and increased physical activity.

Study overview

PURPOSE

To assess the efficacy and safety of RO7795068 for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity.

TOTAL PARTICIPATION TIME

Approximately 85 weeks

STUDY DESIGN

  • Phase 3, randomized, double-blind, placebo-controlled, parallel group study
  • 4 treatment groups — RO7795068 low, medium, or high dose, or placebo
  • 76 weeks of treatment + 5 weeks of safety follow-up
  • Visits approximately every 4 weeks

Who may qualify

  • Age 18 or older
  • Obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 and < 30 kg/m²) with at least 1 weight-related comorbidity
  • Do not have Type 2 Diabetes
  • Willing to adhere to dietary and physical activity counseling
  • Meet additional study health criteria

Why Participate

  • Close medical monitoring at no cost
  • Regular assessments of body weight, anthropometric measurements, and metabolic parameters
  • Contribution to research that may expand treatment options for weight management

COMPENSATION

Up to $3,500

For time and travel

Contact our study team